Cargando…
Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/ https://www.ncbi.nlm.nih.gov/pubmed/30949354 http://dx.doi.org/10.1093/omcr/omz016 |
_version_ | 1783407357402808320 |
---|---|
author | Bulbul, Ajaz |
author_facet | Bulbul, Ajaz |
author_sort | Bulbul, Ajaz |
collection | PubMed |
description | Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case of Vitiligoid irAE (immune-related adverse event) in a non-melanoma solid cancer treated with pembrolizumab. |
format | Online Article Text |
id | pubmed-6440267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64402672019-04-04 Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer Bulbul, Ajaz Oxf Med Case Reports Case Report Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case of Vitiligoid irAE (immune-related adverse event) in a non-melanoma solid cancer treated with pembrolizumab. Oxford University Press 2019-03-29 /pmc/articles/PMC6440267/ /pubmed/30949354 http://dx.doi.org/10.1093/omcr/omz016 Text en © The Author(s) 2019. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Report Bulbul, Ajaz Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title | Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title_full | Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title_fullStr | Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title_full_unstemmed | Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title_short | Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
title_sort | vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/ https://www.ncbi.nlm.nih.gov/pubmed/30949354 http://dx.doi.org/10.1093/omcr/omz016 |
work_keys_str_mv | AT bulbulajaz vitiligoidhypopigmentationassociatedwithpembrolizumabinmetastaticheadandneckcancer |